Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Michael Antony Reed has worked on the following 42 EPO patent applications which have been published in the last five years:

EP12714282

DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

IPC classification:
A61K 31/519, A61P 35/00, A61P 37/00, C07D 487/04
Applicant:
Cellzome Ltd
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12826459

FATTY ACID SYNTHASE INHIBITORS

IPC classification:
A01N 43/42
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP12843835

NEW COMPOUNDS

IPC classification:
A61K 31/52
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12842775

CHEMICAL COMPOUNDS

IPC classification:
A61K 31/52, C07D 473/34
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP12845460

METHOD OF TREATMENT

IPC classification:
A61P 37/00, C12N 9/10
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP12832131

AZAINDAZOLES

IPC classification:
C07D 401/00
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP13704029

METHOD OF TREATING CANCER

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12804047

METHOD OF ADMINISTRATION AND TREATMENT

IPC classification:
A61K 31/4439, A61K 31/535, A61K 38/00, C12N 15/113, G01N 33/574
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13717779

TREATMENT METHOD FOR STEROID RESPONSIVE DERMATOSES

IPC classification:
A61K 9/00, A61K 31/4155, A61K 45/06, A61P 17/00, A61P 17/06
Applicant:
Novartis AG
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP11841263

METHOD OF ADMINISTRATION AND TREATMENT

IPC classification:
A61K 31/501, A61K 45/06, A61P 35/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11825904

FATTY ACID SYNTHASE INHIBITORS

IPC classification:
A01N 43/64, A61K 31/41, A61K 31/4196, A61P 35/00
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14196983

Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors

IPC classification:
A61K 31/50, A61P 7/06, C07D 237/24
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP13845429

COMBINATIONS

IPC classification:
A61K 31/44, A61K 31/519, C07D 487/04
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP11839403

FATTY ACID SYNTHASE INHIBITORS

IPC classification:
A61K 31/537, A61P 35/00, C07D 498/10
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11784238

COMBINATION

IPC classification:
A61K 31/4155, A61K 31/517, G01N 33/574
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP12733916

COMBINATION

IPC classification:
A01N 43/56, A61K 31/4155, A61K 31/69, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP11787314

COMBINATION

IPC classification:
A61K 31/16, A61K 31/40, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP11820572

PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/506, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13870106

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
C07D 213/56
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13864107

COMBINATION

IPC classification:
A61K 31/496
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14702083

FATTY ACID SYNTHASE INHIBITORS

IPC classification:
A61K 31/41, A61P 35/00, C07D 401/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14702081

COMBINATION

IPC classification:
A61K 31/4375, A61K 31/5377, A61P 35/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP11843734

METHOD OF TREATING CANCER

IPC classification:
A61K 31/47, A61K 31/535, A61K 31/5377
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Anthony Joseph Duckett, Mathys & Squire LLP
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14727619

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61K 31/381, A61K 31/4427, A61P 35/00, C07D 401/12, C07D 405/14, C07D 409/12, C07D 409/14, C07D 413/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP14732021

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61K 31/4353, A61P 35/00, C07D 471/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP11778334

INDOLES

IPC classification:
A01N 43/38, A61K 31/405
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP14741958

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61K 31/4436, A61P 35/00, C07D 409/12, C07D 409/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP11842177

METHOD OF TREATMENT WITH BRAF INHIBITOR

IPC classification:
A61K 31/437, A61K 31/44, A61K 31/501, A61K 31/506, A61K 31/519, A61K 45/06, A61P 35/00, C07D 401/00, C07D 417/00, C07D 417/14, C12Q 1/68, G01N 33/53
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11803965

AZAINDAZOLES

IPC classification:
A61K 31/437, A61P 35/00, C07D 471/04, C07D 519/00
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Michael Antony Reed, GlaxoSmithKline Intellectual Property Management Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11760102

CHEMICAL COMPOUNDS

IPC classification:
A61K 31/06, A61K 31/405, A61P 35/00, C07D 403/04, C07D 487/04, C07D 491/04, C07D 495/04
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11784240

COMBINATION THERAPY FOR TREATING CANCER

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/517, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11745417

TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS

IPC classification:
C07D 401/14
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11851046

Combination therapy comprising Gemcitabine for the treatment of pancreatic cancer

IPC classification:
A61K 9/00, A61K 9/20, A61K 9/48, A61K 31/519, A61K 31/7068, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP11778335

INDAZOLES

IPC classification:
A01N 43/38, A61K 31/40, A61P 35/00, C07D 401/12, C07D 401/14, C07D 409/14, C07D 471/04
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15714943

CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS

IPC classification:
A61K 31/4365, A61K 31/519, A61P 25/16, A61P 25/28, A61P 35/00, C07D 487/04, C07D 495/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15767475

NOVEL COMPOUNDS

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
Request for examination was made
EP15767479

NOVEL COMPOUNDS

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
Request for examination was made
EP15767476

NOVEL COMPOUNDS

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
Request for examination was made
EP15767478

NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature